HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Company completes buyback of $200 mil. of 8.25% senior notes due Nov. 1, 2005, Alberto-Culver announces Sept. 15. Redemption will result in $12.6 mil. pre-tax charge in the fourth quarter and will lower net interest expense by approximately $14.3 mil. over remaining original term of the notes, Alberto says. Company likely will use interest expense savings to boost advertising, marketing and other investment to support global brands and businesses, firm notes. Alberto President and CEO Howard Bernick announced plans to increase firm's advertising efforts earlier this month (1"The Rose Sheet" Sept. 13, 2004, In Brief)...

You may also be interested in...


Global sales of VO5 brand are expected to exceed the $300 mil. mark for the first time this year, while worldwide factory sales of the St. Ives brand are approaching $200 mil., President and CEO Howard Bernick says during Prudential Securities Equity Group Back to School Consumer Conference Sept. 8. Alberto-Culver is promoting the VO5, Tresemmé and Soft & Beautiful ranges with TV spots airing in the U.S. and overseas. Company expects to further increase ad spend next year, following a 15% boost this year to $250 mil., exec notes. Bernick reiterates company's interest in buying established skin care brands such as Pfizer's Lubriderm, Schering-Plough's Coppertone and Bristol-Myers Squibb's Keri. Firm previously has indicated it would consider acquiring Lubriderm and Keri (1"The Rose Sheet" Nov. 14, 2001, p. 5)...

Regulatory Measures Could Mitigate EU Coronavirus Risks

As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.

EU Off-Patent Industry Sees ‘Limited Immediate Risk’ From COVID-19

 The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts